FDG and Beyond.
暂无分享,去创建一个
[1] W. Oyen,et al. 18F-FDG PET Early Response Evaluation of Locally Advanced Non–Small Cell Lung Cancer Treated with Concomitant Chemoradiotherapy , 2013, The Journal of Nuclear Medicine.
[2] Wim J. G. Oyen,et al. Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[3] K. Haustermans,et al. Does 11C-choline PET-CT contribute to multiparametric MRI for prostate cancer localisation? , 2013, Strahlentherapie und Onkologie.
[4] T. Vercauteren,et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: initial results of the phase I clinical trial. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] C. Nanni,et al. Role of 18F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[6] B. Hoeben,et al. 18F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome , 2013, The Journal of Nuclear Medicine.
[7] Oliver Jäkel,et al. Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and 68Ga-DOTATOC-PET , 2013, Acta oncologica.
[8] Dimitris Visvikis,et al. Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET , 2013, Acta oncologica.
[9] David Binns,et al. The use of fused PET/CT images for patient selection and radical radiotherapy target volume definition in patients with non-small cell lung cancer: results of a prospective study with mature survival data. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[10] I. Steffen,et al. Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy. , 2013, International journal of radiation oncology, biology, physics.
[11] I. Castiglioni,et al. Predictive value of pre-therapy 18F-FDG PET/CT for the outcome of 18F-FDG PET-guided radiotherapy in patients with head and neck cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Riemer H. J. A. Slart,et al. Value of 11C-methionine PET in imaging brain tumours and metastases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[13] E. Hindié,et al. Evaluation of early response to concomitant chemoradiotherapy by interim 18F-FDG PET/CT imaging in patients with locally advanced oesophageal carcinomas , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[14] Masayuki Matsuo,et al. Clinical value of [¹¹C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors. , 2012, International journal of radiation oncology, biology, physics.
[15] Philippe Lambin,et al. Response Assessment Using 18F-FDG PET Early in the Course of Radiotherapy Correlates with Survival in Advanced-Stage Non–Small Cell Lung Cancer , 2012, The Journal of Nuclear Medicine.
[16] Rodney J Hicks,et al. The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. , 2012, Seminars in nuclear medicine.
[17] Jan-Jakob Sonke,et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[18] G. Fink,et al. Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.
[19] H. Hall,et al. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. , 2012, Nuclear medicine and biology.
[20] Robert Jeraj,et al. Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive? , 2012, The Lancet. Oncology.
[21] S. Sauerland,et al. Randomized Controlled Trials on PET: A Systematic Review of Topics, Design, and Quality , 2012, The Journal of Nuclear Medicine.
[22] Xiaodong Wu,et al. Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. , 2012, IEEE transactions on medical imaging.
[23] H. Christofk,et al. New aspects of the Warburg effect in cancer cell biology. , 2012, Seminars in cell & developmental biology.
[24] K. Haustermans,et al. OC-0050 DOES 11C-CHOLINE PET-CT CONTRIBUTE TO MULTIPARAMETRIC MR IMAGING FOR PROSTATE CANCER LOCALIZATION? , 2012 .
[25] B. Seifert,et al. Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[26] G. Semenza,et al. Hypoxia-Inducible Factors in Physiology and Medicine , 2012, Cell.
[27] Robert Jeraj,et al. PET scans in radiotherapy planning of lung cancer. , 2012, Lung cancer.
[28] F. Mottaghy,et al. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? , 2012, International journal of radiation oncology, biology, physics.
[29] Fréderic Duprez,et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[30] W. Weber,et al. New tracers beyond FDG in head and neck oncology. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[31] J. Kaanders,et al. FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[32] R. Hicks,et al. Role of FDG-PET/CT in staging and follow-up of head and neck squamous cell carcinoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[33] T. Beyer,et al. Simultaneous 68Ga-DOTATOC-PET/MRI for IMRT treatment planning for meningioma: first experience. , 2011, International journal of radiation oncology, biology, physics.
[34] Paul N. Span,et al. Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[35] R. Wahl,et al. The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy. , 2011, Seminars in radiation oncology.
[36] Vincent Gregoire,et al. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. , 2011, Seminars in radiation oncology.
[37] R. T. Ten Haken,et al. Functional and molecular image guidance in radiotherapy treatment planning optimization. , 2011, Seminars in radiation oncology.
[38] Use of PET/CT for staging and radiation therapy planning in patients with non-small cell lung cancer. , 2010 .
[39] Daniela Thorwarth,et al. Physical radiotherapy treatment planning based on functional PET/CT data. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[40] Dirk De Ruysscher,et al. PET scans in radiotherapy planning of lung cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[41] K. Haustermans,et al. Clinical evidence on PET-CT for radiation therapy planning in gastro-intestinal tumors. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[42] Wolfgang A Weber,et al. PET for radiation treatment planning of brain tumours. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[43] C. Haie-meder,et al. Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[44] Luigi Gianolli,et al. Clinical evidence on PET/CT for radiation therapy planning in prostate cancer. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] Johan Bussink,et al. Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[46] Rodney J Hicks,et al. Reproducibility of "intelligent" contouring of gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. , 2007, International journal of radiation oncology, biology, physics.
[47] Tomas Kron,et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. , 2009, International journal of radiation oncology, biology, physics.
[48] P. Grigsby. PET/CT imaging to guide cervical cancer therapy. , 2009, Future oncology.
[49] C. Dooms,et al. Association Between 18F-Fluoro-2-Deoxy-d-Glucose Uptake Values and Tumor Vitality: Prognostic Value of Positron Emission Tomography in Early-Stage Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[50] D. Rubello,et al. Clinical indications for Gallium-68 positron emission tomography imaging. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[51] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[52] Tomio Inoue,et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[53] Jennifer E. Van Eyk,et al. c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism , 2009, Nature.
[54] Ursula Nestle,et al. Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.
[55] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[56] J. Barrio,et al. FLT-PET Imaging of Radiation Responses in Murine Tumors , 2008, Molecular Imaging and Biology.
[57] Andrea Schaefer,et al. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[58] Frederik Maes,et al. Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG? , 2008, Acta oncologica.
[59] Chi V. Dang,et al. The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.
[60] M. Schwaiger,et al. Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[61] Sigrid Stroobants,et al. The maximum uptake of 18F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1α and GLUT-1 in non-small cell lung cancer , 2007 .
[62] Y. Nishiyama,et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[63] M. Schwaiger,et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[64] Anne Bol,et al. A gradient-based method for segmenting FDG-PET images: methodology and validation , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[65] J. Ajani,et al. Early Detection of Chemoradioresponse in Esophageal Carcinoma by 3′-Deoxy-3′-3H-Fluorothymidine Using Preclinical Tumor Models , 2006, Clinical Cancer Research.
[66] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[67] Oksana Gavrilova,et al. p53 Regulates Mitochondrial Respiration , 2006, Science.
[68] E. Eisenhauer,et al. RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.
[69] Michael E Phelps,et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. , 2006, Chest.
[70] Ludwig G Strauss,et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. , 2005, Journal of Nuclear Medicine.
[71] Mark Muzi,et al. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[72] W. Martin,et al. Metabolic Imaging with FDG: A Primer , 2004, Cancer journal.
[73] Torsten Mattfeldt,et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[74] Sven N Reske,et al. 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. , 2003, Cancer research.
[75] L. Bettendorff,et al. ATP‐driven, Na+‐independent inward Cl– pumping in neuroblastoma cells , 2002, Journal of neurochemistry.
[76] S S Gambhir,et al. A tabulated summary of the FDG PET literature. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[77] C. Dang,et al. Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc* , 2000, The Journal of Biological Chemistry.
[78] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[79] S M Larson,et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding , 1997, Cancer.
[80] R A Jungmann,et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[81] Y Yonekura,et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[82] R. Iwata,et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[83] J. Foekens,et al. High incidence of somatostatin receptors in human meningiomas: biochemical characterization. , 1986, The Journal of clinical endocrinology and metabolism.